BioCentury | Sep 2, 2015
Clinical News

Tuning up CARs to target cancer cells

...untreated mice. The researchers generated high- and low-affinity CARs using antibodies Erbitux cetuximab and nimotuzumab (BiomAb-EGFR...
BioCentury | May 12, 2014
Clinical News

Nimotuzumab: Phase III discontinued

...which observed safety issues in patients receiving a combination of cisplatin, vinorelbine, radiotherapy and nimotuzumab. Nimotuzumab...
...between Biocon and CIMAB, has Indian rights to the product. Laboratorios PiSA markets nimotuzumab as Vecthix...
...Laboratorios PiSA , Guadalajara, Mexico Product: Nimotuzumab ( Vecthix , BiomAb-EGFR ) ( DE-766 , OSAG101...
BioCentury | Dec 10, 2012
Company News

InnoKeys, YM BioSciences deal

...YM's CIMYM BioSciences Inc. subsidiary sold its assets related to nimotuzumab to InnoKeys for $2 million...
...80/20 JV between YM and CIMAB S.A. (Havana, Cuba), from which YM had rights to nimotuzumab...
...and CIMAB, has Indian rights to the product. Laboratorios PiSA (Guadalajara, Mexico) markets nimotuzumab as Vecthix...
BioCentury | Nov 7, 2011
Clinical News

Nimotuzumab: Preliminary Phase II data

...tumor necrosis that was deemed possibly related to nimotuzumab. Patients received 150 mg/m 2 IV nimotuzumab...
...between Biocon and CIMAB, has Indian rights to the product. Laboratorios PiSA markets nimotuzumab as Vecthix...
...Bekasi, Indonesia Laboratorios PiSA , Guadalajara, Mexico Product: Nimotuzumab ( Vecthix , BiomAb-EGFR ) ( OSAG101...
BioCentury | Oct 10, 2011
Clinical News

Nimotuzumab: Phase II data

...An open-label, Japanese Phase II trial in 37 evaluable patients showed that nimotuzumab plus cisplatin and...
...between Biocon and CIMAB, has Indian rights to the product. Laboratorios PiSA markets nimotuzumab as Vecthix...
...Bekasi, Indonesia Laboratorios PiSA , Guadalajara, Mexico Product: Nimotuzumab ( Vecthix , BiomAb-EGFR ) ( OSAG101...
BioCentury | Jun 27, 2011
Clinical News

Nimotuzumab cancer data

...12 patients ages 3-13 with diffuse pontine glioma from a pilot compassionate use study of nimotuzumab...
...between Biocon and CIMAB, has Indian rights to the product. Laboratorios PiSA markets nimotuzumab as Vecthix...
...Bekasi, Indonesia Laboratorios PiSA , Guadalajara, Mexico Product: Nimotuzumab ( Vecthix , BiomAb-EGFR ) ( OSAG101...
BioCentury | Jun 13, 2011
Clinical News

Nimotuzumab: Phase II discontinued

...Sankyo, including a planned pivotal trial of nimotuzumab in gastric cancer (see BioCentury, Feb 21). Nimotuzumab...
...between Biocon and CIMAB, has Indian rights to the product. Laboratorios PiSA markets nimotuzumab as Vecthix...
...Bekasi, Indonesia Laboratorios PiSA , Guadalajara, Mexico Product: Nimotuzumab ( Vecthix , BiomAb-EGFR )) ( OSAG101...
BioCentury | Jun 13, 2011
Clinical News

Nimotuzumab: Phase II discontinued

...Sankyo, including a planned pivotal trial of nimotuzumab in gastric cancer (see BioCentury, Feb 21). Nimotuzumab...
...between Biocon and CIMAB, has Indian rights to the product. Laboratorios PiSA markets nimotuzumab as Vecthix...
...Bekasi, Indonesia Laboratorios PiSA , Guadalajara, Mexico Product: Nimotuzumab ( Vecthix , BiomAb-EGFR )) ( OSAG101...
BioCentury | Apr 4, 2011
Finance

ASCO and Beyond

...TSX:YM; NYSE-A:YMI)/Oncoscience AG/Biocon Ltd. (NSE:BIOCON; BSE:BIOCON)/Daiichi Sankyo Co. Ltd. (Tokyo:4568; Osaka:4568)/PT Kalbe Farma Tbk. (Indonesia:KLBF) Nimotuzumab...
BioCentury | Feb 21, 2011
Clinical News

Nimotuzumab: Completed Phase II enrollment

...nimotuzumab in combination with radiation therapy, cisplatin and vinorelbine in patients with stage III NSCLC. Nimotuzumab...
...between Biocon and CIMAB, has Indian rights to the product. Laboratorios PiSA markets nimotuzumab as Vecthix...
...Bekasi, Indonesia Laboratorios PiSA , Guadalajara, Mexico Product: Nimotuzumab ( Vecthix , BiomAb-EGFR )) ( OSAG101...
Items per page:
1 - 10 of 103